Soluble beta-1,3/1,6-glucan

DRUG3 trials

Sponsors

Biotec Pharmacon ASA

Conditions

BurnsFoot UlcerOral Mucositis

Phase 1

Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns

TerminatedNCT00283426

Biotec Pharmacon ASABurns

Start: 2006-01-31End: 2007-03-31Target: 10Updated: 2007-03-19

Phase 2

Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients

CompletedNCT00288392

Biotec Pharmacon ASAFoot Ulcer

Start: 2005-06-30End: 2006-09-30Target: 60Updated: 2006-10-18

The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients

CompletedNCT00289003

Biotec Pharmacon ASAOral Mucositis

Start: 2003-10-31End: 2006-07-31Target: 40Updated: 2007-01-17

Related Papers

Macrophage stimulating agent soluble yeast β‐1,3/1,6‐glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo‐controlled phase <scp>II</scp> study

Journal of Diabetes Investigation2013-12-0263 citations